Gerresheimer's Debt Reprieve Faces Scrutiny as Regulatory Probe Widens

Gerresheimer secures debt extension to 2026, sparking an 18% share surge, but major accounting probe and regulatory crisis remain unresolved.

A decisive 96% vote from creditors has granted Gerresheimer a crucial financial lifeline, sparking an 18% single-day surge in its share price. The agreement extends the maturity on €870 million in promissory notes to September 30, 2026, with banking partners aligning on the same deadline. Crucially, key financial covenants related to leverage ratios are suspended through the third quarter of 2026. Despite this relief, the company's underlying crisis, rooted in accounting irregularities and an expanding regulatory investigation, remains unresolved.

The German packaging specialist aims to deliver its audited 2025 annual report by June 2026, two months ahead of the creditor-imposed deadline. Achieving this would remove a major uncertainty. Operationally, management reports business performance is in line with expectations with a solid order book. Concurrently, the sale process for its US subsidiary Centor Inc., advised by Morgan Stanley, is underway with a double-digit number of interested parties. Centor is carried on the books at €292 million, and a transaction concluded in 2026 could provide a significant boost to the capital structure.

However, the shadow cast by Germany's financial regulator, BaFin, continues to lengthen. In March 2026, BaFin initiated a review of the group's interim accounts for the period from December 2024 to May 2025, citing concrete evidence of potential breaches of accounting rules. This probe has since been expanded to focus on three core areas: potentially misstated lease liabilities with a book value of €65.5 million, incorrectly stated useful lives of capitalized development costs, and unrecognized impairments in the Advanced Technologies segment with a book value of nearly €197 million. No timeline for the investigation's conclusion has been provided.

The accounting errors at the heart of Gerresheimer's troubles are substantial. The company improperly recognized revenue from so-called bill-and-hold transactions, booking sales before goods were delivered—a clear violation of IFRS rules. An independent law firm confirmed the misconduct, which led to a €35 million revenue correction for 2024, a €24 million EBITDA adjustment, and planned write-downs between €220 and €240 million. Germany's audit oversight body, APAS, has subsequently opened a professional disciplinary procedure against auditor KPMG for issuing an unqualified audit opinion for 2024 despite these flaws.

Trading at €21.40, the stock has rallied roughly 25% over the week but remains deeply depressed. It sits about 27% below its 200-day moving average. From a late summer 2023 high of nearly €123, the share price has collapsed by over 80%, a decline that led to its expulsion from the SDAX index. The company's revenue guidance of €2.3 to €2.4 billion for the current year lacks credibility until audited figures are presented, with June 2026 being the earliest possible date for that.

The immediate calendar is sparse, with no quarterly results or annual general meeting scheduled. The next key milestone is the half-year report due on July 14, 2026, though its publication is contingent on the prior delivery of the 2025 annual accounts. For now, the creditor agreement has purchased vital time, but the path to recovery is fraught with regulatory and accounting hurdles that no debt extension can erase.